Abstract
Heat shock proteins (HSP) are upregulated early in response to many insults, including ischemic stroke. This upregulation allows cells to survive potentially lethal conditions via its chaperone functions which can assist in nascent protein folding and the prevention of protein aggregation. After ischemic stroke, HSP can directly interact with various proteins of the tightly regulated programmed cell death known as apoptosis. HSP70 also acts to modulate the inflammatory response following ischemic stroke. The 70 kDa inducible HSP also known as HSP70, has likely been the most extensively evaluated. HSP70 was shown to correlate to the phenomenon of induced tolerance. Studies in genetic mutant models or overexpression using gene transfer or heat stress, further showed that HSP70 led to improvements in brain cell survival. Pharmacological inducers of HSP70 demonstrated similar salutary effects in stroke models, and suggest that this approach has some translational value. Some of these pharmacological inducers have already been studied in humans for treatment of other conditions. Therefore, HSP seem to be neuroprotective, and should be further explored as a potential therapy against stroke and other neurodegenerative diseases.
Similar content being viewed by others
Keywords
1 Introduction
Stroke refers to a range of conditions caused by interruption of the blood supply to the brain, either by occlusion of the cerebral vessels, or by rupture leading to hemorrhage (Kriz and Lalancette-Hebert 2009). Following stroke, the brain undergoes a coordinated stress response which seems to protect it from injury. This cellular response includes the induction of a variety of stress proteins among which, one of the most widely studied are the heat shock proteins (HSP). HSP were originally described because they were highly induced in cells exposed to sublethal heat stress. HSP are a highly conserved family of stress proteins believed to play a role in preventing the aggregation of harmful protein as well as facilitate the synthesis of new proteins via various chaperone function mechanisms such as translocation, degradation, folding, and complex protein assembly. (Giffard and Yenari 2004). Universally expressed HSP family members appear within all subcellular compartments, and play an essential role in normal development and cellular function. After a variety of insults including brain ischemia, inducible forms increase, and appear to be part of a larger orchestrated stress response (Giffard et al. 2008). Over the past few decades, work has shown that some HSP also act as a cytoprotectants. They have also been shown to affect cellular signaling, and have been extensively studied to provide protection against different experimental brain injury models.
2 Heat Shock Proteins
At stroke onset, synthesis of most cellular proteins is reduced; however, different proteins seem to be upregulated, and it is becoming increasingly clear that many of these proteins serve to protect the cell from injury. HSP were among the first of these proteins to be identified and studied. Mammalian HSP have been divided into several families in accordance with molecular weight. These include HSP110, HSP90, HSP70/HSP80, HSP60, and small molecular HSP (smHSP). Constitutive HSP, such as HSP90, HSP40 and cognate HSP70 (HSC70), function together within cells (Lianos et al. 2015). In brain cells, heat stress acts a catalyst to increase inducible HSPs, including HSP27, HSP32 and HSP70 (Lianos et al. 2015). In brain cells, heat stress triggers a robust expression of inducible HSP, such as HSP70, HSP32 and HSP27 (Brown 2007). HSP70, or the 70-kDa class which includes an inducible form also known as HSP72, HSP70i, or simply HSP70 is probably the most studied of this class of protein. It binds to hydrophobic regions of substrate polypeptides in an ATP-dependent manner. ATP hydrolysis then induces a conformational change in HSP70 and triggers substrate folding followed by release (Mayer and Bukau 2005). HSP70 has an N-terminal ATPase domain and a C-terminal substrate-binding domain that helps facilitate protein folding by switching states between open and closed ATP-binding with low and high substrate affinity respectively (Giffard and Yenari 2004). In studies of ischemic stroke, HSP70 was first documented to be induced in brain regions that were relatively resistant to ischemic insults. Hence, the notion of a ‘molecular penumbra’ was introduced, and raised questions as to whether this expression was an epiphenomenon of injury, or an active participant in cell survival (Sharp et al. 2000). A growing body of research has demonstrated repeatedly that HSP70 acts to preserve the brain following experimental insults such as ischemic stroke, neurodegenerative disease, epilepsy, and trauma. HSP70 appears to decreases protein aggregates and intracellular inclusions via chaperone functions. (Giffard et al. 2008). The stress proteins HSP27 and HSP32, or heme oxygenase 1 (HO-1), have also been studied in brain ischemia (Sharp et al. 2013). HSPs, in addition to their role in protein processing, have been shown to preserve the brain via multiple immune response and cell death mechanisms (Giffard and Yenari 2004; Kelly and Yenari 2002).
3 Mechanism of HSP Induction
HSPs interact with various signaling cascades and are responsible for cell growth and differentiation under normal circumstances. Cell stress, including brain injury, causes HSPs to be quickly induced. Insults such as heat, ischemia and other causes of accumulation of unfolded proteins are thought to serve as stimuli for stress protein induction. These unfolded proteins activate heat shock factor (HSF) within the cytosol by dissociating other HSP that are normally bound to HSF (Kim et al. 2012). Once liberated, HSFs are phosphorylated and form trimers. The trimers then enter the nucleus and bind to heat shock elements within the promoters of different heat shock genes, leading to more HSP70 generation (Kim et al. 2018) (Fig. 6.1).
New HSP70 protein, in conjunction with ATP, HSP40 and HSP90, acts to bind denatured proteins and serves as a chaperone at the molecular level by assisting with the repair, refolding and trafficking of damaged proteins in the cell. Inside of the cell, this chaperone complex undergoes multiple iterations to attempt to refold the proteins with binding of the Hip protein to the N-terminus and the Hop protein to the C-terminus of HSP70. HSP70 ultimately helps fold nascent proteins and refold denatured proteins (Lanneau et al. 2010). When refolding does not occur, Bag-1 protein binds to the N-terminus of HSP70, and the E3-ubiquitin ligase CHIP (C-terminus of HSP70/HSC70 interacting protein) binds to the C terminus of HSP70. This complex then interacts with the denatured protein and recruits it to the proteasome where it is ubiquitnated and degraded (Demand et al. 2001). Thus, HSP70 assists in refolding or degradation of damaged proteins.
4 HSP in Ischemic Stroke
Laboratory studies have most commonly used rodent models of middle cerebral artery occlusion (MCAO) and global cerebral ischemia to model the clinical conditions of ischemic stroke and global ischemic brain injury following cardiac arrest, respectively. In both experimental brain ischemia models, induction of HSP has been shown to protect against a variety of acute insults (Sharp et al. 2000). During homeostatic conditions, inducible HSP are present at very low levels; however, its expression is markedly increased following injury. Several studies have reported the relationship between HSP induction and the development of tolerance in ischemic stroke. Direct overexpression of these HSP have been shown to lead to neuroprotection following brain ischemia (Kelly and Yenari 2002).
HSP70 is the most abundant HSP found in cells. After 10 min of focal cerebral ischemia, HSP70 can be detected within the ischemic territory 24 h later. After 1.5 h of middle cerebral artery (MCA) occlusion, much of the MCA territory has undergone infarction, but HSP70 has been detected within the watershed zone between the middle and anterior cerebral arteries. Within these peri-infarct or ‘penumbra’ zones, HSP70 induction occurs primarily in neurons (Sharp et al. 2000). Within zones of infarction and regions adjacent, HSP70 can be observed in glial and endothelial cells (Sharp et al. 2000). Similar observations have been observed in global cerebral ischemia models where HSP70 showed the highest induction within neuronal populations most vulnerable to ischemic injury (Chen and Simon 1997).
Viral vector-mediated HSP70 overexpression has been shown to improve survival of neurons and astrocytes from ischemic and ischemia-like insults, including oxygen glucose deprivation and focal and global cerebral ischemic injury (Giffard and Yenari 2004). Transgenic mice have shown to be protected from ischemic insults when they overexpress HSP70. Similarly, a deficiency in HSP70 in transgenic mice, has shown negative effects. (Kim et al. 2016; Lee et al. 2001). Experimentation utilizing a stroke model demonstrated that intravenous TAT-HSP70, a HSP70 tethered to a TAT motif to enhance BBB penetration, decreased infarct volumes, enhanced neurological outcomes, and increased the survival rate of neural progenitors (Doeppner et al. 2009). The effects of this neuroprotection were associated with fewer apoptotic cells, and elevated levels of anti-apoptotic proteins.
HSP27 has many attributes similar to HSP70, except that ATP is not needed for HSP27’s actions (Stetler et al. 2009). Transgenic mice overexpressing HSP27 subjected to cerebral ischemia demonstrated neuroprotective benefits due to this overexpression (Latchman 2004). protection against ischemic brain and kainate induced neuronal cell death was demonstrated by viral vector-mediated HSP27 overexpression both in vitro and in vivo. (Sharp et al. 2013). HSP27’s capacity to impede apoptosis has been attributed to this protective nature. Research shows that HSP70 and HSP27 prevent mitochondrial dispersion of cytochrome c and the formation of the apoptosome. It is possible that, HSP27 directly interacts with pro-caspase-3 and may work to prohibit Bax translocation to the cell’s mitochondria. HSP27’s neuroprotective properties against cell death have been demonstrated in hippocampal pyramidal neurons against ischemic stroke when the PEP-1-HSP27 fusion protein, a construct to penetrate the BBB, was administered intraperitoneally (An et al. 2008).
HO-1(heme oxygenase-1, HSP32) is an inducible enzyme involved in heme catabolism. Because it contains a HSF in its promoter, it is included as a member of the stress protein family. It acts to transform heme into biliverdin, carbon dioxide and ferrous iron. It shares induction factors with many HSPs (Kelly and Yenari 2002); yet, studies of HO-1 relating to brain ischemia and similar conditions is inconsistent. HO-1 knockout mice have been shown to have worse outcomes in ischemic stroke models, but better outcomes in brain hemorrhage models (Wang and Dore 2007). Circumstances surrounding the location where HO-1 is active and the differential effects of its metabolites may both be possible reasons for these conflicting results.
5 HSP in Neuronal Cell Death Pathways
HSP70 directly or indirectly interferes with cell death pathways such as apoptosis. HSP70 affects several factors of the programmed cell death machinery, both upstream (Stankiewicz et al. 2005; Steel et al. 2004) and downstream of mitochondrial events (Ravagnan et al. 2001). HSP70 has been shown to interrupt cytochrome c release in ischemic stroke models (Lee et al. 2004b; Tsuchiya et al. 2003) and inhibit nuclear translocation of apoptosis inducing factor (AIF) (Matsumori et al. 2005) while decreasing brain infarct size. Overexpression of HSP70 in transgenic mice impedes the translocation of procaspase-9 into the apoptosome, and sequester AIF (Beere et al. 2000). HSP70 also inhibited release of the proapoptotic protein Smac/DIABLO from myocyte mitochondria (Jiang et al. 2005). Mitochondrial HSP70, also known as HSP75 or mortalin assistants act to maintain mitochondrial membrane potential, may and help preserve mitochondrial function and mitochondrial protein import (Geissler et al. 2000) (Voloboueva et al. 2008). HSP27 disrupts the formation of the apoptosome and interacts with cytochrome c, prohibiting cytochrome c release from mitochondria, resulting in a reduction of procaspase-9 activation (Stetler et al. 2009). HSP27 can directly interact with procaspase-3 and inhibit caspase-3 activation (Stetler et al. 2009). When HSP70 is induced in astrocytes, it reduced the cell’s vulnerability to in vitro ischemia-like injury (oxygen glucose deprivation, OGD) and preserved higher ATP levels in stressed cells (Voloboueva et al. 2008). These outcomes were related to reduced reactive oxygen species (ROS) formation and better maintained mitochondrial membrane potential in in vitro model of ischemic stroke (Ouyang et al. 2006) and with better preservation of glutathione levels (Xu and Giffard 1997).
Bcl-2 plays major role in preventing apoptosis. It inhibits the release of cytochrome c and AIF to which are essential to caspase activation. HSP70 overexpression can decrease induction of apoptosis upstream of mitochondria in ischemic stroke models. HSP70 overexpression by viral vectors led to improved survival amongst targeted hippocampal neurons, and this protective effect was associated with increased levels of Bcl-2 protein (Kelly and Yenari 2002). Whether Bcl-2 family members inhibit or promote apoptosis depends on the balance between pro- and anti-apoptotic members which can regulate the mitochondrial membrane permeability transition (Yuan and Yankner 2000); thus, HSP70, through increasing anti-apoptotic Bcl-2 protein expression, may inhibit apoptosis by altering this balance so as to favor cell survival. HSP70 has also been shown to reduce heat-induced apoptosis primarily by blocking mitochondrial translocation of the pro-apoptotic Bcl-2 family member Bax, thereby preventing the release of pro-apoptotic factors (Stankiewicz et al. 2005). Previous studies of HSP27 and its anti-apoptotic activity established that HSP27 can indirectly suppress stress-induced Bax oligomerization and translocation to the mitochondria (Havasi et al. 2008). HSP27 has also been shown to phosphorylate the survival kinase Akt/PKB (Rane et al. 2003) or to inactivate pro-death c-Jun N-terminal kinase (JNK) (Schepers et al. 2005). HSP70 also reduces the activity of apoptosis protease activating factor-1 (Apaf-1), which forms the apoptosome and leads to subsequent activation of caspase-9 (Beere et al. 2000), although others have reported that it does not directly interact with Apaf-1 (Steel et al. 2004).
HSP70 also has the potential to interrupt extrinsic, or receptor-mediated apoptosis. Among various death receptors, Fas is perhaps the most studied. Fas, when bound by its ligand FasL, initiates apoptosis by recruiting caspase-8, which then leads to a cascade that ultimately culminates in caspase-3 activation followed by apoptotic cell death. Through protein profiling, our group discovered that in ischemic brains of HSP70 overexpressing mice exposed to experimental stroke, dynamin was one of the most downregulated proteins. Dynamin is a GTPase typically associated with endocytosis. However, Ivanov and colleagues reported that dynamin also trafficks Fas from the endoplasmic reticulum to the cell’s surface (Ivanov et al. 2006) where it becomes accessible to FasL. In experimental stroke, HSP70 seems to prevent Fas trafficking to the cell surface through interactions with dynamin (Kim et al. 2016). Thus, HSP70 also prevented the extrinsic or receptor-mediated apoptotic pathway through specific chaperone interactions.
6 Role of HSP in Neuroinflammation
HSP are also known to modulate inflammatory responses through both pro- and anti-inflammatory mechanisms. Following acute stroke, immune responses are thought to be mediated through innate pathways, of which HSP have been shown to participate (Srivastava 2002). In the extracellular environment, HSP have been well studied in terms of their role in both innate and adaptive immunity where they appear to assist in and potentiate these responses. HSP70, perhaps the most studied of the HSP with respect to its role in inflammation, appears to play dual roles depending on the nature of the stimulus and the ensuing immune response. As an innate immune modulator, HSP70 can interact with macrophages, microglia, and dendritic cells through Toll-like receptors (TLRs) leading to activation of nuclear factor-kappaB (NF-kB), which induces pro-inflammatory molecules such as cytokines and inducible nitric oxide synthase (iNOS) (Giffard et al. 2008; Srivastava 2002). HSP60 and HSP70 are both thought to interact with TLR 2 and TLR4 (Asea 2008); however, some of this work has been questioned, since some preparations of recombinant HSP may contain low levels of endotoxin, which is the classic ligand for TLR4 (Gaston 2002). With regard to the adaptive immune system, extracellular HSP70 complexed with peptides elicit CD8+ T-cell responses after exogenous administration. Immunization of mice with these same complexes can elicit CD4 responses, indicating that HSP can act as an adjuvant. These HSP70-peptide complexes can also interact with the macrophage/dendritic cell CD 40, CD91, or lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) and aid in antigen presentation.
HSP70 has also been reported to have anti-inflammatory effects. It has been shown to decrease the release of pro-inflammatory factors such as matrix metalloproteinases (MMPs), reactive oxygen species (ROS) and inhibit NF-kB activation. Intracellular overexpression of HSP70 or its intracellular induction through heat stress has been shown to decrease inflammatory cell production of nitric oxide (NO) and iNOS expression while blocking NF-kB activation in glial cells of the brain (Feinstein et al. 1996). Heat stress has also been correlated to the reduction of tumor necrosis factor-alpha (TNF-α) and ROS generation. Heat shock-induced HSP70 also correlated to reduced expression inflammatory cytokines such TNF-α and interleukin-6 (IL-6) (Van Molle et al. 2002), while induction of HSP70 in macrophages blocked LPS-induced TNF, IL-1, IL-10 and IL-12 expression (Ding et al. 2001). In an experimental model of intracerebral hemorrhage, overexpression of HSP70 decreased TNF-α expression and interrupted blood brain barrier (BBB) disruption, edema formation, and neurological dysfunction (Manaenko et al. 2010).
HSP70 overexpression by heat stress also blocks NADPH oxidase activity in neutrophils and promotes superoxide dismutase (SOD) in phagocytes (Polla et al. 1995). In heat-pretreated astrocytes, HSP70 overexpression also interrupts the phosphorylation of IkB, JNK and p38 and blunts DNA binding of transcription factors, such as NF-kB, activator portien-1 (AP-1) and signal transducer and activator of transcription factor 1 (STAT-1), effectively downregulating the expression of pro-inflammatory genes (Kim et al. 2015) (Fig 6.2). In another study, prior-heat stress lead to interruption of the inflammatory response, and this was associated with inhibition of NF-kB translocation to the nucleus (Guzhova et al. 1997; Heneka et al. 2000). HSP70 has also been shown to interrupt NF-kB dissociation by preventing the phosphorylation of the inhibitor of kB (IkB) (Feinstein et al. 1996). A few studies have shown that HSP70 can also bind to and inhibit NF-kB and/or its regulatory proteins (Ran et al. 2004; Zheng et al. 2008), although how it does this may depend on the nature of the stimulus. In a cell death model induced by TNF-α, HSP70 inhibited IkB kinase (IKK) activity directly, whereas in a model of ischemic stroke, HSP70 appeared to associate with NF-kB and IkB, thus preventing IkB phosphorylation by IKK. The inhibition of NF-kB by HSP70 was thus shown to have a neuroprotective effect in a stroke model by preventing transcription of several immune genes (Zheng et al. 2008).
HSP70 also appears to inhibit generation of matrix metalloproteinases (MMPs), a family of extracellular proteases thought to contribute to reperfusion injury and brain hemorrhage in experimental stroke models. In an in vitro study of HSP70 overexpression astrocytes, MMP-9 expression, also under the transcriptional control by NF-kB, was inhibited following exposure to ischemia-like insults (Lee et al. 2004a). HSP70 overexpression also seemed to similarly decrease MMP-2 (Lee et al. 2004a). Interestingly, MMP-9 expression is regulated by NF-kB, whereas MMP-2 is not. However, our prior study in cultured astrocytes (Kim et al. 2015) and studies in alveolar macrophages indicate that HSP70 can inhibit STAT-1 (Howard et al. 2010), and STAT-1 has been linked to MMP-2 expression (Johnston et al. 2000). Further, HSP70 also appears to prevent MMP processing from its pro, or inactive form to its cleaved or active form. Thus, it is clear that HSP have a myriad of roles, some of which modulate immune responses toward both pro-and anti-inflammatory phenotypes, although the effects in acute stroke models suggests that the overall response is anti-inflammatory.
7 Clinical Translation of HSP
After ischemic stroke, strategies to increase intracellular HSP70 might be significant in many neurological conditions related to cell death or pro-inflammatory processes. While heat stress may be impractical to translate, pharmacological induction of HSP70 is not impossible. A few studies have now shown that pharmacological induction of HSP70 can protect the brain in experimental stroke and brain injury models. The best studied HSP70 inducers are the ansamycins, geldanamycin (GA) and 17-(Allylamino) geldanamycin (17-AAG). These compounds induce HSP70 through their ability to inhibit HSP90, and have been shown to protect the brain from brain injury (Kim et al. 2012) (Fig 6.2). Additionally, GA and 17-AAG have already been studied in clinical trials, albeit for other indications. Clinical trials of GA were halted due to liver toxicity (Supko et al. 1995), but the less toxic GA analogue 17-AAG with similar HSP90-antagonistic functions have been studied in phase 3 clinical trials as cancer therapy (Porter et al. 2010). With its solubility in aqueous solution, 17-(2-dimethylaminoethyl) amino-17-demethoxygeldanamycin(17-DMAG), was developed for cancer treatment, but was also found to improve outcome following experimental stroke, while decreasing activation of microglia and NF-kB through inhibition of IκB phosphorylation (Qi et al. 2014).
Also, other HSP70-inducing pharmaceuticals include the purine-based compounds, the resorcinols, and other novel chemotypes. The purine series is a synthetic class that was modeled after the way ansamycins co-opt ADP to bind the HSP90 ATP binding site (Jones et al. 2011). BIIB021 (also named CNF-2024) is the best-known purine based HSP70-inducer so far, and is a potent HSP90-inhibitor (Porter et al. 2010). It can be given orally, and has been studied up to the phase II level in cancer studies with an acceptable safety profie (Jhaveri et al. 2012). The resorcinols are compounds based on radicicol, but to date, there have been no studies evaluating resorcinols’ effect on brain injury (Porter et al. 2010), although considering related studies to inhibit HSP90, there would be good reason to study this class of compounds in stroke models. Since radicicol itself tends to degrade in vivo, there are some variants designed to overcome this pharmaceutical limit, such as NVP-AUY922 and AT-13387. There is also growing interest in another HSP70 inducer, geranylgeranylacetone (GGA) known for its antiulcer properties. Administration of GGA after middle cerebral infarction showed that it anti-inflammatory effect was due to up-regulation of HSP70 through protein kinase C induction (Yasuda et al. 2005). Zhao et al. found that pretreatment with GGA led to neuroprotection by reducing neuronal cell apoptosis and microglial activation in a traumatic brain injury model (Zhao et al. 2013). No clinical studies of HSP70 inducers/HSP90 inhibitors have been carried out for neuroprotection against acute neurological insults, but considering robust laboratory data, ample clinical experience in cancer patients, and renewed interest in neuroprotection considering a prominent role for acute revascularization in stroke patients (Mizuma et al. 2018), this may be area ripe for investigation.
8 Conclusions
Several studies have investigated the beneficial effects of HSPs after ischemic stroke. Several laboratories have shown that HSPs lead to neuroprotective effects in experimental stroke and should thus be explored as a therapeutic target. One translatable approach may be through pharmacological induction of HSPs through several already available HSP90 inhibitors, some of which have already been tested in humans. There are a few laboratory studies in preclinical animal model that have shown the beneficial effects of induced HSP70 for treatment of ischemic stroke and brain trauma. Multiple protective mechanisms of HSP70 make it a particularly attractive target, as it has the potential to target several aspects of ischemic injury. Considering recent clinical advances in the treatment of acute stroke, the therapeutic value of HSP should be considered for further investigation.
Abbreviations
- 17-AAG:
-
17-(Allylamino) geldanamycin
- 17-DMAG:
-
17-(2-dimethylaminoethyl) amino-17-demethoxygeldanamycin
- AIF:
-
apoptosis inducing factor
- Apaf-1:
-
apoptosis protease activating factor-1
- AP-1:
-
activator portien-1
- ATP:
-
adenosine triphosphate
- BBB:
-
blood brain barrier
- DIABLO/smac:
-
direct IAP-binding mitochondrial protein/second mitochondria-derived activator of caspases
- GA:
-
geldanamycin
- GGA:
-
geranylgeranylacetone
- HO-1:
-
heme oxygenase-1
- HSC:
-
heat shock cognate
- HSF:
-
heat shock factor
- HSP:
-
heat shock protein
- smHSP:
-
small molecular HSP
- IkB:
-
inhibitor of kappaB
- IKK:
-
IkB kinase
- IL-1:
-
interleukin-1
- LOX-1:
-
low density lipoprotein receptor-1
- NO:
-
nitric oxide
- iNOS:
-
inducible nitric oxide synthase
- JNK:
-
c-Jun N-terminal kinase
- MCA:
-
middle cerebral artery
- MMP:
-
matrix metalloproteinase
- NADPH:
-
nicotinamide adenine dinucleotide phosphate
- NF-kB:
-
nuclear factor-kappaB
- iNOS:
-
inducible nitric oxide synthase
- OGD:
-
oxygen glucose deprivation
- PKB:
-
protein kinase B
- ROS:
-
reactive oxygen species
- STAT-1:
-
signal transducer and activator of transcription factor-1
- TLR:
-
Toll-like receptor
- TNF:
-
tumor necrosis factor
References
An JJ, Lee YP, Kim SY, Lee SH, Lee MJ, Jeong MS, Kim DW, Jang SH, Yoo KY, Won MH et al (2008) Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult. FEBS J 275:1296–1308
Asea A (2008) Heat shock proteins and toll-like receptors. Handb Exp Pharmacol:111–127
Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR (2000) Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2:469–475
Brown IR (2007) Heat shock proteins and protection of the nervous system. Ann N Y Acad Sci 1113:147–158
Chen J, Simon R (1997) Ischemic tolerance in the brain. Neurology 48:306–311
Demand J, Alberti S, Patterson C, Hohfeld J (2001) Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol 11:1569–1577
Ding XZ, Fernandez-Prada CM, Bhattacharjee AK, Hoover DL (2001) Over-expression of hsp-70 inhibits bacterial lipopolysaccharide-induced production of cytokines in human monocyte-derived macrophages. Cytokine 16:210–219
Doeppner TR, Nagel F, Dietz GP, Weise J, Tonges L, Schwarting S, Bahr M (2009) TAT-Hsp70-mediated neuroprotection and increased survival of neuronal precursor cells after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 29:1187–1196
Feinstein DL, Galea E, Aquino DA, Li GC, Xu H, Reis DJ (1996) Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation. J Biol Chem 271:17724–17732
Gaston JS (2002) Heat shock proteins and innate immunity. Clin Exp Immunol 127:1–3
Geissler A, Krimmer T, Bomer U, Guiard B, Rassow J, Pfanner N (2000) Membrane potential-driven protein import into mitochondria. The sorting sequence of cytochrome b(2) modulates the deltapsi-dependence of translocation of the matrix-targeting sequence. Mol Biol Cell 11:3977–3991
Giffard RG, Yenari MA (2004) Many mechanisms for hsp70 protection from cerebral ischemia. J Neurosurg Anesthesiol 16:53–61
Giffard RG, Han RQ, Emery JF, Duan M, Pittet JF (2008) Regulation of apoptotic and inflammatory cell signaling in cerebral ischemia: the complex roles of heat shock protein 70. Anesthesiology 109:339–348
Guzhova IV, Darieva ZA, Melo AR, Margulis BA (1997) Major stress protein Hsp70 interacts with NF-kB regulatory complex in human T-lymphoma cells. Cell Stress Chaperones 2:132–139
Havasi A, Li Z, Wang Z, Martin JL, Botla V, Ruchalski K, Schwartz JH, Borkan SC (2008) Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem 283:12305–12313
Heneka MT, Sharp A, Klockgether T, Gavrilyuk V, Feinstein DL (2000) The heat shock response inhibits NF-kappaB activation, nitric oxide synthase type 2 expression, and macrophage/microglial activation in brain. J Cereb Blood Flow Metab 20:800–811
Howard M, Roux J, Lee H, Miyazawa B, Lee JW, Gartland B, Howard AJ, Matthay MA, Carles M, Pittet JF (2010) Activation of the stress protein response inhibits the STAT1 signalling pathway and iNOS function in alveolar macrophages: role of Hsp90 and Hsp70. Thorax 65:346–353
Ivanov VN, Ronai Z, Hei TK (2006) Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem 281:1840–1852
Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823:742–755
Jiang B, Xiao W, Shi Y, Liu M, Xiao X (2005) Heat shock pretreatment inhibited the release of Smac/DIABLO from mitochondria and apoptosis induced by hydrogen peroxide in cardiomyocytes and C2C12 myogenic cells. Cell Stress Chaperones 10:252–262
Johnston JB, Jiang Y, van Marle G, Mayne MB, Ni W, Holden J, McArthur JC, Power C (2000) Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. J Virol 74:7211–7220
Jones Q, Voegeli TS, Li G, Chen Y, Currie RW (2011) Heat shock proteins protect against ischemia and inflammation through multiple mechanisms. Inflamm Allergy Drug Targets 10:247–259
Kelly S, Yenari MA (2002) Neuroprotection: heat shock proteins. Curr Med Res Opin 18(Suppl 2):s55–s60
Kim N, Kim JY, Yenari MA (2012) Anti-inflammatory properties and pharmacological induction of Hsp70 after brain injury. Inflammopharmacology 20:177–185
Kim JY, Yenari MA, Lee JE (2015) Regulation of inflammatory transcription factors by heat shock protein 70 in primary cultured astrocytes exposed to oxygen-glucose deprivation. Neuroscience 286:272–280
Kim JY, Kim N, Zheng Z, Lee JE, Yenari MA (2016) 70-kDa Heat Shock Protein Downregulates Dynamin in Experimental Stroke: A New Therapeutic Target? Stroke 47:2103–2111
Kim JY, Han Y, Lee JE, Yenari MA (2018) The 70-kDa heat shock protein (Hsp70) as a therapeutic target for stroke. Expert Opin Ther Targets 22:191–199
Kriz J, Lalancette-Hebert M (2009) Inflammation, plasticity and real-time imaging after cerebral ischemia. Acta Neuropathol 117:497–509
Lanneau D, Wettstein G, Bonniaud P, Garrido C (2010) Heat shock proteins: cell protection through protein triage. Sci World J 10:1543–1552
Latchman DS (2004) Protective effect of heat shock proteins in the nervous system. Curr Neurovasc Res 1:21–27
Lee SH, Kim M, Yoon BW, Kim YJ, Ma SJ, Roh JK, Lee JS, Seo JS (2001) Targeted hsp70.1 disruption increases infarction volume after focal cerebral ischemia in mice. Stroke 32:2905–2912
Lee JE, Kim YJ, Kim JY, Lee WT, Yenari MA, Giffard RG (2004a) The 70 kDa heat shock protein suppresses matrix metalloproteinases in astrocytes. Neuroreport 15:499–502
Lee SH, Kwon HM, Kim YJ, Lee KM, Kim M, Yoon BW (2004b) Effects of hsp70.1 gene knockout on the mitochondrial apoptotic pathway after focal cerebral ischemia. Stroke 35:2195–2199
Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, Dionigi G, Roukos DH (2015) The role of heat shock proteins in cancer. Cancer Lett 360:114–118
Manaenko A, Fathali N, Chen H, Suzuki H, Williams S, Zhang JH, Tang J (2010) Heat shock protein 70 upregulation by geldanamycin reduces brain injury in a mouse model of intracerebral hemorrhage. Neurochem Int 57:844–850
Matsumori Y, Hong SM, Aoyama K, Fan Y, Kayama T, Sheldon RA, Vexler ZS, Ferriero DM, Weinstein PR, Liu J (2005) Hsp70 overexpression sequesters AIF and reduces neonatal hypoxic/ischemic brain injury. J Cereb Blood Flow Metab 25:899–910
Mayer MP, Bukau B (2005) Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci 62:670–684
Mizuma A, You JS, Yenari MA (2018) Targeting Reperfusion Injury in the Age of Mechanical Thrombectomy. Stroke 49:1796–1802
Ouyang YB, Xu LJ, Sun YJ, Giffard RG (2006) Overexpression of inducible heat shock protein 70 and its mutants in astrocytes is associated with maintenance of mitochondrial physiology during glucose deprivation stress. Cell Stress Chaperones 11:180–186
Polla BS, Stubbe H, Kantengwa S, Maridonneau-Parini I, Jacquier-Sarlin MR (1995) Differential induction of stress proteins and functional effects of heat shock in human phagocytes. Inflammation 19:363–378
Porter JR, Fritz CC, Depew KM (2010) Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 14:412–420
Qi J, Han X, Liu HT, Chen T, Zhang JL, Yang P, Bo SH, Lu XT, Zhang J (2014) 17-Dimethylaminoethylamino-17-demethoxygeldanamycin attenuates inflammatory responses in experimental stroke. Biol Pharm Bull 37:1713–1718
Ran R, Zhou G, Lu A, Zhang L, Tang Y, Rigby AC, Sharp FR (2004) Hsp70 mutant proteins modulate additional apoptotic pathways and improve cell survival. Cell Stress Chaperones 9:229–242
Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, Chen Q, McLeish KR, Klein JB (2003) Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 278:27828–27835
Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, Jaattela M, Penninger JM, Garrido C, Kroemer G (2001) Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 3:839–843
Schepers H, Geugien M, van der Toorn M, Bryantsev AL, Kampinga HH, Eggen BJ, Vellenga E (2005) HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp Hematol 33:660–670
Sharp FR, Lu A, Tang Y, Millhorn DE (2000) Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 20:1011–1032
Sharp FR, Zhan X, Liu DZ (2013) Heat shock proteins in the brain: role of Hsp70, Hsp 27, and HO-1 (Hsp32) and their therapeutic potential. Transl Stroke Res 4:685–692
Srivastava P (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2:185–194
Stankiewicz AR, Lachapelle G, Foo CP, Radicioni SM, Mosser DD (2005) Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. J Biol Chem 280:38729–38739
Steel R, Doherty JP, Buzzard K, Clemons N, Hawkins CJ, Anderson RL (2004) Hsp72 inhibits apoptosis upstream of the mitochondria and not through interactions with Apaf-1. J Biol Chem 279:51490–51499
Stetler RA, Gao Y, Signore AP, Cao G, Chen J (2009) HSP27: mechanisms of cellular protection against neuronal injury. Curr Mol Med 9:863–872
Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305–315
Tsuchiya D, Hong S, Matsumori Y, Kayama T, Swanson RA, Dillman WH, Liu J, Panter SS, Weinstein PR (2003) Overexpression of rat heat shock protein 70 reduces neuronal injury after transient focal ischemia, transient global ischemia, or kainic acid-induced seizures. Neurosurgery 53:1179–1187. discussion 1187-1178
Van Molle W, Wielockx B, Mahieu T, Takada M, Taniguchi T, Sekikawa K, Libert C (2002) HSP70 protects against TNF-induced lethal inflammatory shock. Immunity 16:685–695
Voloboueva LA, Duan M, Ouyang Y, Emery JF, Stoy C, Giffard RG (2008) Overexpression of mitochondrial Hsp70/Hsp75 protects astrocytes against ischemic injury in vitro. J Cereb Blood Flow Metab 28:1009–1016
Wang J, Dore S (2007) Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain 130:1643–1652
Xu L, Giffard RG (1997) HSP70 protects murine astrocytes from glucose deprivation injury. Neurosci Lett 224:9–12
Yasuda H, Shichinohe H, Kuroda S, Ishikawa T, Iwasaki Y (2005) Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone in permanent focal cerebral ischemia. Brain Res 1032:176–182
Yuan J, Yankner BA (2000) Apoptosis in the nervous system. Nature 407:802–809
Zhao Z, Faden AI, Loane DJ, Lipinski MM, Sabirzhanov B, Stoica BA (2013) Neuroprotective effects of geranylgeranylacetone in experimental traumatic brain injury. J Cereb Blood Flow Metab 33:1897–1908
Zheng Z, Kim JY, Ma H, Lee JE, Yenari MA (2008) Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab 28:53–63
Acknowledgments
This study was funded by grants from the National Institutes of Health (R01 NS 106441, RO3 NS101246), Department of Defense and the Veteran’s Merit Award (I01 BX000589) to MAY, Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1D1A1B03933017) to JYK and a National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT & Future Planning (NRF-2016M3C7A1905098) to JEL. Grants to MAY were administered by the Northern California Institute for Research and Education, and supported by resources of the Veterans Affairs Medical Center, San Francisco, California.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kim, J.Y., Huang, M., Lee, J.E., Yenari, M.A. (2019). Role of Heat Shock Proteins (HSP) in Neuroprotection for Ischemic Stroke. In: Asea, A., Kaur, P. (eds) Heat Shock Proteins in Neuroscience. Heat Shock Proteins, vol 20. Springer, Cham. https://doi.org/10.1007/978-3-030-24285-5_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-24285-5_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24284-8
Online ISBN: 978-3-030-24285-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)